Financial OpportunitiesIf approved, Quoin may be eligible to receive a Pediatric Review Voucher which can potentially be sold for over $100M, providing nondilutive financing.
Market PotentialNetherton Syndrome remains a very difficult to treat disease with no approved disease-modifying therapeutic options, thus an approved therapy has significant market potential.
Regulatory ProgressQuoin is continuing to progress the development of QRX003 for treating Netherton Syndrome, with two whole body studies being conducted for regulatory submissions.